Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown cause. It is theorized to occur in genetically susceptible individuals.
The outcome in RA is compromised when diagnosis and treatment are delayed. The clinical course of RA is generally one of exacerbations and remissions. Approximately 40% of patients with this disease become disabled after 10 years. 
Actual Medical Prognosis
RA that remains persistently active for longer than one year is likely to lead to joint deformities and disability.  The prognosis of RA is generally much worse among patients with positive Rheumatoid Factor (RF) results. For example, the presence of RF in blood has been associated with severe erosive disease. [3, 4] However, the absence of RF does not necessarily portend a good prognosis.
World Stem Cells Clinic’s Advanced Stem Cell Treatment (ASCT) for Rheumatoid Arthritis
With the patient’s own adult stem cells, previously stimulated and then enhanced and expanded at our laboratory we address some of the underlying causes of the disease. Stem cells induce physical changes in the body to help it heal and gain a better quality of life. Our studies have proven our stem cell protocol to be safe, and does not require complete suppression of the immune system.
The modification of the autoimmune dysfunction with stabilization and some reversal of the disease are shown in a number of studies below. [5 – 10]
A study designed and conducted at World Stem Cells Clinic for Rheumatoid Arthritis successfully delivered:
- A stop of progression or greatly elongation of remission time of the illness.
- Reduction in joint inflammation, deformity and decreased morning stiffness.
- Better articular movements which turn into improved walking and hand motion for dressing and other activities.
- Alleviation of general pain.
- We have frequent reports from our patients about having an improvement in their quality of life.
If you or a person you care about suffers from one of these or have any other related symptoms please do not hesitate to contact us to find out if we are conducting further studies.
News and references supporting our studies
 Lipsky PE. Harrison’s Principles of Internal Medicine. In: Isselbacher KJ, Braunwald E, Fauci AS, et al.Rheumatoid arthritis. 17th ed. New York, NY: McGraw-Hill; 1994:1648-55.
 Sokka T, Kautiainen H, Möttönen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol. Aug 1999;26(8):1681-5. LINK: www.ncbi.nlm.nih.gov/pubmed/10451062
 Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol. Feb 2007;26(2):201-4.LINK: www.ncbi.nlm.nih.gov/pubmed/16572283
 Vencovsky J, Machacek S, Sedova L, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis. May 2003;62(5):427-30. LINK:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754544/
 The potential of stem cell therapy for osteoarthritis and rheumatoid arthritis. Keerthi N1, Chimutengwende-Gordon M, Sanghani A, Khan W. Curr Stem Cell Res Ther. 2013 Nov;8(6):444-50. LINK:www.ncbi.nlm.nih.gov/pubmed/24016323
 Whole body tracking of superparamagnetic iron oxide nanoparticle-labelled cells – a rheumatoid arthritis mouse model. Hareklea Markides, et al. Stem Cell Research & therapy 2013, 4: 126. LINK:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854718/
 Mesenchymal stem cells and repair of the synovial joint. Mao JJ. Stem-cell-driven regeneration of synovial joints. Biol Cell 2005; 97(5): 289-301. LINK: www.ncbi.nlm.nih.gov/pubmed/15836429
 Mesenchymal stem cells in connective tissue engineering and regenerative medicine: applications in cartilage repair and osteoarthritis therapy. Mobasheri A1, Csaki C, Clutterbuck AL, Rahmanzadeh M, Shakibaei M. Histol Histopathol. 2009 Mar;24(3):347-66. LINK: www.ncbi.nlm.nih.gov/pubmed/19130405
 Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. Snowden JA1, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar J, Verburg R, Szer J, Taylor K,Joske D, Rule S, Bingham SJ, Emery P, Burt RK,Lowenthal RM, Durez P, McKendry RJ, Pavletic SZ, Espigado I,Jantunen E, Kashyap A, Rabusin M, Brooks P, Bredeson C, Tyndall A. J Rheumatol. 2004 Mar;31(3):482-8. LINK:www.ncbi.nlm.nih.gov/pubmed/14994391
 Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Richard K. Burt, et al. Arthritis & Rheumatism Volume 50, Issue 8, pages 2466–2470, August 2004. Copyright © 2004 by the American College of Rheumatology. LINK: www.ncbi.nlm.nih.gov/pubmed/15334459